RSV Economic Burden and Resource Use Among Older Adults in Five European Countries

December 2023–June 2024 survey data from 682 physicians on 1,581 patients aged 60+ with confirmed RSV across France, Germany, Italy, Spain, and the UK. Diana Mendes authored this dataset, which describes healthcare visits, tests, hospital stays, drug use, supportive care needs, and productivity loss. Direct and indirect costs are calculated using country-specific unit costs, with patients stratified by symptom duration and hospitalization status.

Use Cases

• Model direct healthcare costs based on reported mean visits, tests, hospital stays, and drug use.
• Analyze indirect economic burden based on reported work impairment, paid and unpaid productivity loss.
• Compare resource utilization across patient subgroups stratified by symptom duration (acute, ongoing, post-acute) and hospitalization.
• Estimate country-specific costs using the applied country-specific unit costs methodology.

Strengths

• Data covers 1,581 patients across five European countries (France, Germany, Italy, Spain, UK).
• Includes detailed cost breakdowns, with mean direct costs ranging from €320 to €6,900 per patient.
• Stratifies patients by clinically relevant categories: symptom duration (<4, 4–<12, 12–52 weeks) and hospitalization.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect geographic bias inherent to the five surveyed European countries.

Provenance

Source

Adelphi RSV Disease Specific Program (DSP™) survey.

Collection Method

Cross-sectional survey of physicians and patients.

Time Range

December 2023–June 2024.

Freshness

Last updated 2026-03-19 06:49:56; freshness should be verified.

Geography

France, Germany, Italy, Spain, United Kingdom.